Biosense Webster, Inc., a worldwide leader in the diagnosis and
treatment of cardiac arrhythmias, will showcase its portfolio of cutting
edge innovative technologies at the 2013 Boston AF meeting. Boston AF,
now in its 18th year, provides a scientific forum for health
care professionals to learn about advances in research and therapeutics
in the field of atrial fibrillation.
At the meeting, Biosense Webster will showcase its complete portfolio of
market-leading technologies and present an array of innovative solutions
for Electrophysiologists and Allied Health Professionals including:-
Clinical Support, Global Education and Training Programs, Technical
Service, Patient Education, and other resources to support the expanded
access to ablation treatment.
The new CARTOALARA™ Module for the company's CARTO®
3 System will be introduced at Boston AF. The CARTOALARA™
Module seamlessly combines a fluoroscopy image and CARTO® 3
System maps into a single view and helps lower fluoroscopy levels to as
low as reasonably achievable. Complementing the accuracy of the CARTO®
System proprietary magnetic navigation technology, the CARTOALARA™
Module is an open architecture technology designed to work
with a variety of industry leading fluoroscopy systems allowing
customers to convert many of their legacy systems with minimal effort.
"This new advance allows electrophysiologists to navigate with
confidence from one integrated view, said Shlomi Nachman, Worldwide
President, Biosense Webster. "The safety of our physician customers and
their patients is very important to us and we are leading an
industry-wide initiative with the goal of dramatically reducing
fluoroscopy use in the EP lab without compromising safety."
Combined with the CARTO® System Advanced Catheter Location
(ACL) Technology, Fast Anatomical Mapping (FAM) capability and its
CONNECTION OF CHOICE® functionality, the CARTOALARA™ Module
adds a new dimension to the CARTO® System's established
electroanatomical mapping accuracy, reinforcing user trust and
The CARTOALARA™ Module will be commercially available
in the United States and Europe starting in February 2013.
About AF and cardiac ablation
Atrial Fibrillation is the most prevalent arrhythmia, and is a leading
cause of stroke among people 65 years and older. Worldwide, it is
estimated that 20 million people have AF, yet only ~130,000 are treated
with ablation every year. The public health implications of AF are a
growing concern because those with AF are at an increased risk of
morbidity and mortality as well as a reduced quality of life.
Most patients with AF today are treated with anti-arrhythmic drugs
(AADs), even though about half of them are refractory to these drugs.
During cardiac ablation, energy is delivered through the catheter to
those areas of the heart muscle causing the abnormal heart rhythm. This
energy "disconnects" the pathway of the abnormal rhythm. Cardiac
ablation is commonly used for "simple" arrhythmias, like
Wolff-Parkison-White Syndrome and atrioventricular nodal re-entry
tachycardia (AVNRT), and is increasingly being used for more complex
arrhythmias like ventricular tachycardia and atrial fibrillation.
THERMOCOOL® Navigation Catheters are approved for drug
refractory recurrent symptomatic paroxysmal atrial fibrillation, when
used with CARTO® Systems (excluding NAVISTAR® RMT
About Biosense Webster, Inc.
Biosense Webster, Inc., a Johnson & Johnson company, pioneered EP
diagnostic catheters more than 20 years ago and continues to lead the
industry as an innovative provider of advanced cardiac diagnostic,
therapeutic, and mapping tools. As the leader in EP navigation systems
and ablation therapy, Biosense Webster, Inc. has technology that
includes the largest installed base of cardiac mapping navigation
systems worldwide in leading hospitals and teaching institutions. For
more information about Biosense Webster and its products, please visit: www.biosensewebster.com
(this site is intended for US visitors only).
Always verify catheter tip location using fluoroscopy or IC signals
and consult the CARTO® System User Guide
regarding recommendations for fluoroscopy use.
Biosense Webster, Inc. 2013
[ Back To NFVZone's Homepage ]